Parthenon Therapeutics
Before joining Parthenon Therapeutics, Thomas was a Director of Discovery Biology and first scientist hired at Scholar Rock, Inc., a Cambridge biotechnology company that focuses on the discovery and development of novel growth factor-targeting antibodies for the treatment of musculoskeletal diseases, fibrosis, and cancer. During his nine year tenure at Scholar Rock, Thomas built up the company's TGFβ portfolio and led the discovery of SRK-181, a selective inhibitor of latent TGFβ1 activation that is currently being investigated in the DRAGON Phase 1 clinical trial in patients with locally advanced or metastatic solid tumors. He is an inventor on several granted patents and international patent applications. Thomas received postgraduate training at Harvard Medical School and Children's Hospital Boston in the laboratory of Dr. Timothy Springer and received a Ph.D from ETH Zurich, Switzerland.
This person is not in any offices
Parthenon Therapeutics
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on rigorous, groundbreaking research, we are designing a portfolio of drug candidates to treat the right patients at the right time.